drug
Ofev
Marketedupdated 6mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4indications
investigational
Pulmonary Fibrosis
all catalysts(4)
Trials studying Ofev
- phase2A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
- phase3A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
- phase1Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
- —A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
- —NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
- —An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
- phase1A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
- phase3Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 6, 2027
106 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Dec 7, 2029patentUS 9907756*PED3.0y
- Dec 7, 2029patentUS 9907756*PED3.0y
- Dec 4, 2029patentUS 10105323*PED3.0y
- Dec 4, 2029patentUS 10105323*PED3.0y
- Jun 7, 2029formulationUS 99077562.5y
- Jun 7, 2029formulationUS 99077562.5y
- Jun 4, 2029formulationUS 101053232.5y
- Jun 4, 2029formulationUS 101053232.5y
- Jul 8, 2026patentUS 10154990*PED
- Jul 8, 2026patentUS 10154990*PED
- Apr 1, 2026patentUS 6762180*PED
- Apr 1, 2026patentUS 6762180*PED
- Jan 8, 2026method-of-use (U-2620)US 10154990
- Jan 8, 2026method-of-use (U-2620)US 10154990
- Oct 1, 2025compositionUS 6762180
- Oct 1, 2025compositionUS 6762180
FDA exclusivities (4)
- Mar 6, 2027PEDPediatric (6mo bonus)106d
- Mar 6, 2027PEDPediatric (6mo bonus)106d
- Sep 6, 2026ODE-261Orphan Drug (7y)
- Sep 6, 2026ODE-261Orphan Drug (7y)
News(5)
- Bristol Myers dips on ‘confounding’ lung drug resultsOnly the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.biopharma_dive · 1mo ago
- Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitorEndeavor BioMedicines solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing to…fiercebiotech · 1mo ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 1mo ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 4mo ago
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.biopharma_dive · 6mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that